Business Description
AnaptysBio Inc
NAICS : 325412
SIC : 2834
ISIN : US0327241065
Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 26.08 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.24 | |||||
| Beneish M-Score | -0.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -38.6 | |||||
| 3-Year EBITDA Growth Rate | -99.4 | |||||
| 3-Year EPS without NRI Growth Rate | -99.6 | |||||
| 3-Year FCF Growth Rate | -103.1 | |||||
| 3-Year Book Growth Rate | -38.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 3.66 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.62 | |||||
| 9-Day RSI | 24.26 | |||||
| 14-Day RSI | 28.61 | |||||
| 6-1 Month Momentum % | 6.31 | |||||
| 12-1 Month Momentum % | 34.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.23 | |||||
| Quick Ratio | 10.23 | |||||
| Cash Ratio | 9.8 | |||||
| Days Sales Outstanding | 49.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.9 | |||||
| Shareholder Yield % | -23.65 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -245.01 | |||||
| Net Margin % | -289.75 | |||||
| FCF Margin % | -182.37 | |||||
| ROE % | -236.31 | |||||
| ROA % | -36.55 | |||||
| ROIC % | -248.15 | |||||
| ROC (Joel Greenblatt) % | -723.1 | |||||
| ROCE % | -30.87 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.71 | |||||
| PB Ratio | 4.95 | |||||
| Price-to-Tangible-Book | 4.96 | |||||
| EV-to-EBIT | 0.04 | |||||
| EV-to-Forward-EBIT | -0.08 | |||||
| EV-to-EBITDA | 0.06 | |||||
| EV-to-Forward-EBITDA | -0.07 | |||||
| EV-to-Revenue | -0.12 | |||||
| EV-to-Forward-Revenue | 0.16 | |||||
| EV-to-FCF | -0.04 | |||||
| Price-to-Net-Current-Asset-Value | 10.61 | |||||
| Price-to-Net-Cash | 20 | |||||
| Earnings Yield (Greenblatt) % | 2268.65 | |||||
| FCF Yield % | -26.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AnaptysBio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 52.1 | ||
| EPS (TTM) (€) | -5.583 | ||
| Beta | 0.48 | ||
| Volatility % | 79.08 | ||
| 14-Day RSI | 28.61 | ||
| 14-Day ATR (€) | 0.898024 | ||
| 20-Day SMA (€) | 17.575 | ||
| 12-1 Month Momentum % | 34.86 | ||
| 52-Week Range (€) | 13.6 - 36.2 | ||
| Shares Outstanding (Mil) | 30.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AnaptysBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AnaptysBio Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
AnaptysBio Inc Frequently Asked Questions
What is AnaptysBio Inc(STU:AN6)'s stock price today?
The current price of STU:AN6 is €14.00. The 52 week high of STU:AN6 is €36.20 and 52 week low is €13.60.
When is next earnings date of AnaptysBio Inc(STU:AN6)?
The next earnings date of AnaptysBio Inc(STU:AN6) is 2025-03-11 Est..
Does AnaptysBio Inc(STU:AN6) pay dividends? If so, how much?
AnaptysBio Inc(STU:AN6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers